Evidence map›Paper›PMID 27159181›Full record

ReviewBone marrow transplantation2016

Can we agree on patient-reported outcome measures for assessing hematopoietic cell transplantation patients? A study from the CIBMTR and BMT CTN.

B E Shaw, S J Lee, M M Horowitz, W A Wood, J D Rizzo, K E Flynn

Abstract readReview
PubMed Publisher
In one paragraph

Review in Bone marrow transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Guideline
  2. Health-Related Quality of Life after Autologous Stem Cell Transplantation for Multiple Myeloma.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2018
    Pooled it
  3. Trial
  4. Article
  5. Article
  6. Observational
  7. Review
  8. Review
  9. Observational
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency.Hematology. American Society of Hematology. Education Program · 2020
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

B E ShawDepartment of Medicine, CIBMTR (Center for International Blood and Marrow Transplant Research), Froedert and the Medical College of Wisconsin, Milwaukee, WI, USA.
S J LeeClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
M M HorowitzDepartment of Medicine, CIBMTR (Center for International Blood and Marrow Transplant Research), Froedert and the Medical College of Wisconsin, Milwaukee, WI, USA.
W A WoodDivision of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.
J D RizzoDepartment of Medicine, CIBMTR (Center for International Blood and Marrow Transplant Research), Froedert and the Medical College of Wisconsin, Milwaukee, WI, USA.
K E FlynnDepartment of Medicine, Center for Patient Care and Outcomes Research, Medical College of Wisconsin, Milwaukee, WI, USA.

Funding

Blood and Marrow Transplant Clinical Trials Network DCC- The Medical College of Wisconsin, Inc.U24HL138660 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI Steven M. DeVine, Mehdi Hussain Hamadani · 2017 to 2026
$71.4M
NHLBI NIH HHS U24 HL138660
6 · The paper itself

Abstract

Much research into the impact of hematopoietic cell transplantation (HCT) on recipients' symptoms, functioning and health-related quality of life uses diverse patient-reported outcome (PRO) measures. Robust conclusions regarding PROs in HCT patients are constrained by methodological issues, including the use of multiple different and noncomparable assessment measures. We reviewed 114 publications addressing PROs in HCT patients. Although three multi-item measures were most frequently used (FACT-BMT, n=28; European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30, n=26; and SF-36, n=26), 25 additional measures were used in more than one study. Another 50 measures were used in single studies. Over 50% of studies used more than one measure. We recommend that the field agrees upon a set of measures to address the core domains important to patients, to reduce heterogeneity and allow comparisons across studies and between different populations. Measures should be available in a free and easily accessible manner internationally. We discuss the relative benefits of the National Institutes of Health-supported Patient-Reported Outcomes Measurement Information System (PROMIS) system to achieve these goals. To further address these issues, the Blood and Marrow Transplant Clinical Trials Network has recently created a task force to implement PROMIS measures alongside traditional PRO measures in future clinical trials. Robust comparisons between measures in this setting may allow for the development of a standard for HCT patients.

Indexed as

Patient Reported Outcome MeasuresHematopoietic Stem Cell TransplantationHumansOutcome Assessment, Health CareQuality Indicators, Health CareReproducibility of ResultsTreatment Outcome

Identifiers

PMID27159181

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.